Integra Lifesciences (IART) Lowers Q4 Revenue Guidance Amid Tiss

Integra Lifesciences (IART) reduced its Q4 revenue forecast to $413M-$433M, below analyst expectations of $432.21M, citing challenges in its Tissue Reconstruction segment and Cincinnati recovery. The company's P/S ratio is 0.63, below historical and industry averages, reflecting market caution. IART's GF Score is 69, indicating moderate overall health with strong momentum but weak growth and financial strength.

Original reporting
Published Oct 21, 2026, 10:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The guidance revision signals weaker near‑term revenue, potentially prompting a sell‑off, but the stock remains undervalued on a sales basis.

02

Market read

Guidance miss is the primary catalyst for IART and may influence peer stocks in the medical‑device sector.

03

What to watch

Insider buying and strong momentum score may indicate confidence that the guidance dip is temporary.

Relevance 7/10Novelty 8/10Timing: today

Background

Integra Lifesciences (IART) is a mid‑cap medical‑device company with two segments: Codman Specialty Surgical and Tissue Technologies.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra Lifesciences lowered its Q4 revenue guidance to $413‑$433 million, below consensus estimates.

Expected impact

likely downside as investors price in weaker revenue outlook

Evidence & confidence

Guidance is below consensus and marks a downgrade in expectations for a mid‑cap medical‑device company.

Market effects

May weigh on other medical‑device and regenerative‑medicine stocks as investors reassess growth outlooks.

Primarily U.S. market impact; limited effect on broader indices.

Low global relevance beyond the healthcare sector.

Counterpoint

The low price‑to‑sales multiple could still present a value opportunity if the recovery in Cincinnati exceeds expectations.

Key entities

  • Integra Lifesciences Holdings Corp

    Subject of the article; provides medical devices and regenerative medicine products.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.